Article Details
Retrieved on: 2025-07-23 16:18:01
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in Duchenne patients who ...
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here